Sign in Subscribe

kerecis

Kerecis becomes Iceland's first Unicorn after being acquired by Coloplast for up to $1.3 billion

Kerecis becomes Iceland's first Unicorn after being acquired by Coloplast for up to $1.3 billion

Kerecis has signed an agreement with Coloplast, the Danish medical device manufacturer, to be acquired for up to $1.3 billion, making them Iceland’s first Unicorn company. In today’s Kerecis business meeting, which took place in Ísafjörður where they have a manufacturing facility, Fertram Sigurjónsson, founder and CEO

Kerecis's raises $100m Series D

Kerecis's raises $100m Series D

As Northstack reported at the end of last month, Kerecis has received a significant investment from multiple investors including the Danish investment firm KIRKBI. That coverage was based on a leaked letter that was sent to Kerecis’s shareholders that the media had obtained The coverage can be seen below.

Kerecis secures a $40M investment from the owners of LEGO

Kerecis secures a $40M investment from the owners of LEGO

According to recent press coverage, KIRKBI, a Danish investment firm best known for being the owner of the brand LEGO, will invest $40M in the Icelandic company Kerecis. With this transaction, KIRKBI will hold a 6.4 percent stake in the company resulting in a valuation of Keracis of approximately

Kerecis raises $21m in loans and convertible notes to fuel expansion

Kerecis raises $21m in loans and convertible notes to fuel expansion

Kerecis, the medical fish skin company, recently announced it had raised $21m from Silicon Valley Bank and previous investors to support the company’s expansion plans in the US. Of the $21m, $15m are in the form of a revolving line of credit from Silicon Valley Bank, and $6m in

Kerecis partners with National Hospital of Iceland to evaluate effectiveness of Kerecis products on COVID-19 patients

Kerecis partners with National Hospital of Iceland to evaluate effectiveness of Kerecis products on COVID-19 patients

Kerecis and the National Hospital of Iceland are conducting a randomized, controlled, double-blind clinical study to evaluate the effectiveness of the Kerecis Omega3 Viruxide system on COVID-19 patients. The trial follows successful off-label use on Italian patients with COVID-19 symptoms. Omega3 Viruxide is a virucidal and bactericidal system used in